Agendia, Inc.: Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer

Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendia's

Related Keywords

Germany ,West German ,Dennis Riedl ,William Audeh ,Oleg Gluz ,Kerry Harrington ,German Study Group ,Agendia Inc ,University Of Cologne ,Breast Center Niederrhein ,West German Study Group ,Mammaprint Low Risk ,Scientific Director ,Hospital Bethesda ,Chief Medical Officer ,Agendia ,Nnounces ,First ,Patient ,Unrolled ,Roofs ,Registry ,Trial ,Etermine ,Toptimal ,Treatment ,Ability ,Corgo ,Chemotherapy ,Premenopausal ,Women ,Early ,Breast ,Dancer ,